CBD beneficios

• Autores: Paula Bujalance Latasa, Ariadna Gracia Prad, Oumaima Aboulmakarim Rabbani, Silvia Carnicer Izaguerri
• Localización: Revista Sanitaria de Investigación, ISSN-e 2660-7085, Vol. 6, Nº. 5, 2025
• Idioma: español
• Enlaces
  • Texto completo
• Resumen
  • español

    El CBD es un compuesto no psicoactivo que deriva de la planta Cannabis sativa.

    Recientemente se ha demostrado que el CBD tiene un gran potencial farmacológico, ya que posee varias propiedades muy interesantes para la medicina actual, entre ellas: propiedades antiinflamatorias, neuroprotectoras, ansiolíticas y anticonvulsivas. Sin embargo, el miedo a la adicción ha hecho que no se haya estudiado lo suficiente ni extendido terapéuticamente.

  • English

    CBD is a non-psychoactive compound derived from the Cannabis sativa plant.

    CBD has recently been shown to have great pharmacological potential, as it possesses several very interesting properties for today’s medicine, including: anti-inflammatory, neuroprotective, anxiolytic and anticonvulsant properties. However, fear of addiction has meant that it has not been sufficiently studied or therapeutically extended.

• Referencias bibliográficas
  • Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis...
  • Russo EB. Cannabidiol claims and misconceptions: (trends in pharmacological sciences 38, 198-201; 2017). Trends Pharmacol Sci [Internet]....
  • Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics [Internet]....
  • Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early phase in the development of cannabidiol as a treatment for addiction:...
  • Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) [Internet]. 2012;5(5):529–52. Disponible...
  • Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin:...
  • Pérez C. Cannabidiol (CBD). Mecanismos de acción y efectos terapéuticos. Perspectivas de uso en epilepsias [Internet]. Observatorio Español...
  • Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor: GPR55,...
  • Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D, Cottone P, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation...
  • Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues:...
  • Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression....
  • Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms...
  • Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome....
  • Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial...
  • Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic...
  • Bergamaschi MM, Queiroz RHC, Zuardi AW, Crippa JAS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf [Internet]....
  • Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19....
  • Qué tipos de CBD existen [Internet]. Cbdorganics.es. [citado el 26 de marzo de 2025]. Disponible en: https://cbdorganics.es/que-tipos-de-cbd-existen/